Navigation Links
Celebrex May Reduce Levels of Lung Cancer Biomarker
Date:6/1/2008

ssor of medicine at City of Hope Cancer Center in Duarte, Calif.

Lung cancer is a notoriously difficult-to-treat disease, largely because it's usually not caught in its early stages.

"Lung cancer is an extraordinarily challenging tumor type," confirmed Dr. Howard Sandler, moderator of the news conference and a professor of radiation oncology and urology at the University of Michigan.

Prevention, therefore, becomes key. Quitting smoking or never smoking, of course, greatly reduces the risk for this disease. But there are people who beat the odds even if they smoke, just as there are nonsmokers who do develop lung cancer.

"We need to continue to refine what a high-risk population is, both clinical and biological characteristics, and that leads us into biomarkers," Kim said. The researchers were primarily interested in how Celebrex might affect Ki-67, a protein that may be related to cell proliferation.

The cox-2 enzyme is expressed in both precancerous lesions in lung tissue, as well as in lung cancer, and it has an inflammatory aspect that can stimulate more cell growth within the lung.

This study involved more than 200 patients, all of whom had a history (current or prior) of a greater than 20-pack-years cigarette habit. All participants underwent biopsies at the opening of the study, at three months and again at six months.

They were then randomized to take either Celebrex or a placebo for three months, after which they either continued on that course or switched to the other arm.

Over three months, high-dose Celebrex (400 milligrams twice a day) did reduce expression levels of Ki-67, as well as the cox-2 enzyme and a third biomarker, NF-kappa-B.

The effect was seen in both current and former smokers but was stronger in current smokers, Kim said.

No cardiac side effects were seen in the group, although previous research showed a benefit to Celebrex in reducing colon
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex, Naproxen Wont Prevent Mental Decline
4. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
5. New study: Pine bark reduces perimenopausal symptoms
6. Different method of evaluating the urinary tract system reduces radiation dose
7. Saline Reduces Mortality for Brain Injury Patients
8. New approaches to reduce scarring
9. Fruity vegetables and fish reduce asthma and allergies
10. New study: Pine bark extract reduces ADHD symptoms in children
11. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... 2015 The World Scout League Commission ... to potential EMTs and firefighters, recently announced its decision ... way to raise charitable donations for age-related research. The ... will be held on March 29, 2015; registration will ... at 3:30 p.m. , To participate in the ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2
... SAN JOSE, Calif., Dec. 28 For the majority of Americans ... New Year brings mixed emotions: the renewed resolution to shed pounds ... those goals. Helping to bridge the gap between resolutions and reality, ... an unexpected nutritious punch. , Mushrooms are one such example - ...
... thought to occur at the synapse, since synapse loss ... amyloid beta (Aβ) plays an important role in early ... effect on the plasticity of dendritic spines. ... neurons) that relay electrical impulses in the brain. A ...
... biggest factor standing in people,s way , MONDAY, Dec. 28 (HealthDay ... Americans will resolve that this year, they,ll exercise ... so many of those resolutions broken? , New research may shed ... know that exercise is good for them and can improve their ...
... 28 Former NY Giant great and NFL Hall of ... the Year Award for Chiropractic in New York State for ... honor at the NY Chiropractic Council,s annual convention in Tarrytown, ... instrumental in leading H.O.P.E. Day, which stands for Helping Other ...
... CAQH® announced today that Aetna and WellPoint, together ... health plans to earn certification for electronically exchanging administrative ... Information Exchange® (CORE) Phase II rules. , Aetna ... of the CORE rules, which represent an all-payer solution ...
... only one sibling affected , MONDAY, Dec. 28 (HealthDay ... as diet and chemical exposure may play a role ... , American and Spanish researchers compared the DNA of ... that can influence the expression of genes) in healthy ...
Cached Medicine News:Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 2Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 3Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 4Health News:How amyloid beta reduces plasticity related to synaptic signaling 2Health News:Top Reasons Those 'Get Fit' Resolutions Don't Stick 2Health News:Top Reasons Those 'Get Fit' Resolutions Don't Stick 3Health News:All-Time Giant Great Receives Humanitarian of the Year Award 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 3
(Date:2/27/2015)... LEXINGTON, Mass. , Feb. 27, 2015   ... GEVA ), a biopharmaceutical company developing therapeutic products ... Rare Disorders™ (NORD™), the European Organisation for Rare ... around the world in observing Rare Disease Day. ... each year, patient organizations, industry, and other participants ...
(Date:2/27/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the fourth quarter and full year ended ... transformative year for PTC. We are now a growing ... therapies in the rare disease space," stated Stuart W. ... are proud to bring the first treatment for Duchenne ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... and markets innovative proprietary products to treat voiding dysfunctions, ... Annual ROTH Conference on Tuesday, March 10, 2015. ... Reynolds , Chief Financial Officer, will present at 4:00 ... one at the conference at the Ritz Carlton in ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
Latex agglutination test for the qualitative and semiquantitative determination of rheumatoid factor in serum....
The SYNCHRON CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 C...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
... choosing a non-contact diagnostic lens, doctors have to ... view and high magnification. Now, with the ... Optical, doctors can have both in one lens. ... view available in a non-contact lens paired with ...
Medicine Products: